Belite Bio Announces Uplisting to the Nasdaq Global Select Market
Key Highlights
- ➤BLTE approved to transfer from Nasdaq Capital Market to Global Select Market
- ➤Trading on Nasdaq Global Select starts October 19, 2026, under BLTE ticker
- ➤Uplisting reflects compliance with stricter financial and liquidity standards
- ➤DRAGON Phase 3 trial of tinlarebant met its primary endpoint
Expert Statements
Tom Lin, Chairman and Chief Executive Officer of Belite Bio
“Uplisting to the Nasdaq Global Select Market is a significant milestone for Belite Bio and reflects our ongoing financial discipline and business execution,”
Tom Lin, Chairman and Chief Executive Officer of Belite Bio
“We look forward to leveraging this enhanced platform to drive growth and create further value for our shareholders, as we continue to execute on our work to bring the potential first-ever approved treatment to patients living with Stargardt disease.”
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio(®)” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has received approval from Nasdaq to transfer the listing of its securities from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the Nasdaq Global Select Market will commence at the open of market on October 19, 2026, under the Company’s existing ticker symbol “BLTE.”
The Nasdaq Global Select Market is the highest of the three Nasdaq market tiers. The uplisting to this Market reflects the Company’s compliance with the Nasdaq Global Select Market’s more stringent financial and liquidity standards, as well as the Company’s continued progress in strengthening its financial profile and capital markets presence. The transition to this highest tier of the Nasdaq market is expected to enhance the Company’s visibility among institutional investors, improve liquidity, and broaden market recognition.
Get started
Create a free account to read the full story.